2174264_eisai_logo

Eisai withdraws application for neurodegenerative-disease drug in Japan

pharmafile | March 22, 2016 | News story | Manufacturing and Production, Research and Development Eisai, mecobalamin, neurodegenerative disease 

Pharma major Eisai (TYO: 4523) on Tuesday said the Japanese regulators have stalled the approval of its drug to treat a neurodegenerative disease, citing insufficient information.

As a result the company has withdrawn its new drug application for mecobalamin, in Japan, following a meeting with the Pharmaceuticals and Medical Devices Agency (PMDA). Eisai said it will “carefully reconsider the future development strategy” for mecobalamin after consultation with the regulatory authority.

In May last year, Eisai filed for regulatory approval for mecobalamin as a treatment for amyotrophic lateral sclerosis (ALS).

ALS is an intractable, progressive, neurodegenerative disease that causes severe muscle atrophy and weakness in the muscles. Currently, there are limited treatment options for the disorder.

As the main cause of death is respiratory failure due to paralysis of the respiratory muscles, without the use of an artificial respirator, death occurs within about 3 and 6 years from the onset of the disease. In Japan, the incidence rate of ALS ranges between 1.1 to 2.5 per 100,000 people, and onset most often occurs between the ages of 50 to 60.

Mecobalamin is approved and marketed as a treatment for peripheral neuropathies and other conditions.

Anjali Shukla

Related Content

robina-weermeijer-so1l3jsdd3y-unsplash_2

Eisai shares new data for Leqembi for Alzheimer’s treatment

Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL …

Alzheimer's brain

FDA grants Alzheimer’s disease drug Leqembi full approval

Japanese pharmaceutical company Eisai and US-based biotechnology company Biogen have announced that the US Food …

shutterstock_273326141

Eisai and Wren Therapeutics join forces to tackle neurodegenerative synucleinopathies

Eisai has forged an exclusive research partnership with Wren Therapeutics to develop new approaches in …

Latest content